Does ivermectin cure and/or prevent COVID-19?

A double-blind clinical trial to repurpose and assess the efficacy and safety of ivermectin in COVID-19

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN40302986

Enrollment

Registered

2020-05-26

Start date

2020-06-22

Completion date

Unknown

Last updated

2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 (SARS-CoV-2 infection) Infections and Infestations

Interventions

This will be a randomized parallel-group study of three groups of COVID-positive Nigerian patients with 10 - 15 post-exposure COVID-positive subjects in each treatment arm. There shall be three treat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. COVID-positive people 2. All ages and genders 3. Informed consent given after Emergency IRB approval

Exclusion criteria

Exclusion criteria: 1. COVID-negative people 2. Those who refuse to give informed consent 3. Pregnant women in first trimester of pregnancy

Design outcomes

Primary

Measure	Time frame
Viral RNA load measured using quantitative branched DNA (bDNA), reverse transcriptase-polymerase chain reaction (RT-PCR), and qualitative transcription-mediated amplification at baseline and 1, 2, 4, 7, 10, 12, 14 days	—

Secondary

Measure	Time frame
Measured on days 0, 2, 4, 7, 10, 12, 14: 1. Body temperature measured using infrared temperature sensor 2. Heart Rate measured using a pulse oximeter device 3. Respiratory rate measured using respiratory movement method 4. PaO2 measured using pulse oximeter 5. Symptom checklist especially: 5.1. Anosmia/cacosmia measured using University of Pennsylvania Smell Identification Test 5.2. Respiratory: cough frequency, intensity, dyspnea measured using Likert scale 5.3. GIT symptoms: nausea, vomiting, diarrhoea, abdominal pain, blood in stool or vomit, depending on reports taken from the patient and observations by the nurse over the past 24 hours 5.4. Genitourinary system: dysuria, urine colour, frothiness measured using reports taken from patient and observations by the nurse over the preceding 24 hours 5.5. Cardiovascular system: chest pain, palpitations, tiredness, lassitude, dyspnea on exertion measured using reports taken from the patient and observations by the nurses 5.6. Central nervous system: headache, as reported by the patient, and change in consciousness level as measured using the Glasgow Coma Scale	—

Measure

Time frame

Measured on days 0, 2, 4, 7, 10, 12, 14: 1. Body temperature measured using infrared temperature sensor 2. Heart Rate measured using a pulse oximeter device 3. Respiratory rate measured using respiratory movement method 4. PaO2 measured using pulse oximeter 5. Symptom checklist especially: 5.1. Anosmia/cacosmia measured using University of Pennsylvania Smell Identification Test 5.2. Respiratory: cough frequency, intensity, dyspnea measured using Likert scale 5.3. GIT symptoms: nausea, vomiting, diarrhoea, abdominal pain, blood in stool or vomit, depending on reports taken from the patient and observations by the nurse over the past 24 hours 5.4. Genitourinary system: dysuria, urine colour, frothiness measured using reports taken from patient and observations by the nurse over the preceding 24 hours 5.5. Cardiovascular system: chest pain, palpitations, tiredness, lassitude, dyspnea on exertion measured using reports taken from the patient and observations by the nurses 5.6. Central nervous system: headache, as reported by the patient, and change in consciousness level as measured using the Glasgow Coma Scale

—

Countries

Nigeria

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026